Pacira Biosciences signed the agreement for the acquisition Oct. 11. Flexion’s lead product, Zilretta, is used for osteoarthritic knee pain.
“Zilretta is a highly complementary commercial asset that allows us to provide physicians with another tool in their pain management armamentarium to tackle osteoarthritis earlier in the patient journey as we continue to redefine the role of opioids as a last resort rescue medication,” David Stack, Pacira’s CEO, said in the release.
